Moderna says RSV vaccine is 84% effective at preventing disease in older adults

Moderna says RSV vaccine is 84% effective at preventing disease in older adults


A woman receives a booster dose of the Moderna coronavirus disease (COVID-19) vaccine at a vaccination centre in Antwerp, Belgium, February 1, 2022.

Johanna Geron | Reuters

Moderna on Tuesday said its vaccine targeting respiratory syncytial virus is effective at preventing disease in older adults.

The vaccine was 83.7% effective at preventing lower respiratory tract disease, defined as two or more symptoms, in people ages 60 and older, according to the Boston biotech company. It was 82.4% effective at preventing lower respiratory tract disease with three or more symptoms.

No safety concerns have been identified during the clinical trial of the vaccine, according to Moderna. The safety and efficacy data from the trial will be published in a peer-reviewed journal, according to the company. The clinical trial has enrolled about 37,000 people across 22 countries.

Moderna said it plans to file an application for approval by the Food and Drug Administration in the first half of this year. There currently is no FDA-approved vaccine for RSV.

Moderna’s stock rose nearly 7% in extended trading.

RSV infections kill between 6,000 and 10,000 older adults every year and result in 60,000 to 120,000 hospitalizations, according to the Centers for Disease Control and Prevention.

The U.S. suffered an unusually severe RSV season last fall among children and older adults as the public largely stopped practicing public health measures implemented in response to the Covid-19 pandemic, such as masking and social distancing.

Moderna’s RSV vaccine uses the same messenger RNA technology as the company’s successful Covid shots. The Covid vaccine turned Moderna into a global name and delivered windfall profits, but it remains the company’s only commercially available product and demand is fading.

The Boston biotech company faces growing pressure to demonstrate that other products in its pipeline will successfully come to market. Morgan Stanley estimates the market for an adult RSV vaccine is $7 billion to $10 billion.

CNBC Health & Science

Read CNBC’s latest global health coverage:



Source

Virtual chronic care company Omada Health files for IPO
Health

Virtual chronic care company Omada Health files for IPO

Omada Health smart devices in use. Courtesy: Omada Health Virtual care company Omada Health filed for an IPO on Friday, the latest digital health company that’s signaled its intent to hit the public markets despite a turbulent economy. Founded in 2012, Omada offers virtual care programs to support patients with chronic conditions like prediabetes, diabetes […]

Read More
Startup Teal Health wins FDA approval for at-home test for cervical cancer screening
Health

Startup Teal Health wins FDA approval for at-home test for cervical cancer screening

The Food and Drug Administration on Friday approved the first-ever at-home test for cervical cancer screening, developed by San Francisco-based startup Teal Health. The company began developing the prototype for its Teal Wand just over five years ago. The concept was to make cervical cancer screening more accessible via telehealth and a test that could […]

Read More
These 6 portfolio names pledged big U.S. investments since Trump took office again
Health

These 6 portfolio names pledged big U.S. investments since Trump took office again

Many of the biggest U.S. companies have pledged to invest trillions of dollars in the United States since President Donald Trump started his second term — including six names in our portfolio. These moves are aimed at aligning companies with the president’s vision for a new global trade order designed to bring manufacturing jobs back […]

Read More